UCB S.A. - SWOT Analysis company profile is the essential source for top-level company data and information. UCB S.A. - SWOT Analysis examines the company’s key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy.
UCB is a global biopharmaceutical company. The company focuses on severe diseases in the fields of central nervous system (CNS) disorders and autoimmune and inflammatory diseases (AIID). It has operations in about 40 countries in Europe, North America, Asia, Africa, Oceania and South America. It is headquartered in Brussels, Belgium and employed 8,898 people as of December 31, 2010. The company recorded revenues of E3,218 million ($4,269.3 million*) during the financial year (FY) ended December 2010, an increase of 3.3% over 2009. The operating profit of the company was E204 million ($270.6 million*) during FY2010, a decrease of 75.6% over 2009. The net profit was E103 million ($136.7 million*) in FY2010, a decrease of 79.9% over 2009. * Calculated using a constant conversion rate of E1 = $1.3267 for year ended December 31, 2010.
Scope of the Report
Provides all the crucial information on UCB S.A. required for business and competitor intelligence needs
Contains a study of the major internal and external factors affecting UCB S.A. in the form of a SWOT analysis as well as a breakdown and examination of leading product revenue streams of UCB S.A.
Data is supplemented with details on UCB S.A. history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available statement from UCB S.A.
Reasons to Purchase
Support sales activities by understanding your customers’ businesses better
Understand prospective partners and suppliers
Keep fully up to date on your competitors’ business structure, strategy and prospects
Obtain the most up to date company information available